肺炎治療薬の市場規模、シェア、成長分析：製品別、薬剤クラス別、投与経路別、感染様式別、年齢層別、地域別 - 産業予測 2025～2032年

肺炎治療薬市場規模は2023年に112億9,000万米ドルと評価され、予測期間（2025-2032年）のCAGRは8.4%で、2024年の122億4,000万米ドルから2032年には233億3,000万米ドルに成長する見通しです。

世界の肺炎治療薬市場は、特に高齢者や免疫不全者の肺炎有病率の上昇に牽引されて成長を遂げています。市中肺炎は依然として注目すべき問題であり、早期診断と治療の重要性に対する認識が高まっています。このような背景から、診断技術や評価ツールの進歩に拍車がかかり、ヘルスケアプロバイダーの治療ガイドラインが強化されています。市場開発では、多様な抗生物質、抗ウイルス薬、支持療法が提供されるとともに、標的治療を開発するための個別化医療にも焦点が当てられています。しかし、抗生物質耐性やヘルスケアへのアクセス格差といった課題は依然として残っています。全体として、現在進行中の医療の進歩と人口動態の変化は、肺炎治療薬市場の今後数年間の有望な軌道を示しています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• ケーススタディ
• 規制情勢
• 特許分析

肺炎治療薬市場規模：製品別& CAGR（2025-2032）

• 市場概要
• 薬物
• ワクチン
• 酸素療法

肺炎治療薬市場規模：薬剤クラス別& CAGR（2025-2032）

• 市場概要
• 抗菌薬
• 抗ウイルス薬
• 抗真菌薬

肺炎治療薬市場規模：投与経路別& CAGR（2025-2032）

• 市場概要
• 経口
• 非経口
• 吸入

肺炎治療薬市場規模：感染様式別& CAGR（2025-2032）

• 市場概要
• 院内肺炎（HAP）
• 市中肺炎（CAP）
• 人工呼吸器関連肺炎（VAP）

肺炎治療薬市場規模：年齢層別& CAGR（2025-2032）

• 市場概要
• 小児
• 成人
• 高齢者

肺炎治療薬市場規模：流通チャネル別& CAGR（2025-2032）

• 市場概要
• 病院薬局
• 小売薬局
• オンライン薬局

肺炎治療薬市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• Pfizer Inc.（USA）
• Merck & Co., Inc.（USA）
• GlaxoSmithKline plc（UK）
• AstraZeneca（UK）
• Novartis AG（Switzerland）
• Sanofi（France）
• Bayer AG（Germany）
• Eli Lilly and Company（USA）
• Abbott Laboratories（USA）
• Cipla Inc.（India）
• Lupin Pharmaceuticals Ltd.（India）
• Nabriva Therapeutics AG（Austria）
• Biotest AG（Germany）
• SetLance SRL（Italy）
• Biogen（USA）
• F. Hoffmann-La Roche Ltd.（Switzerland）
• Johnson & Johnson（USA）
• Gilead Sciences, Inc.（USA）

結論と提言

Pneumonia Therapeutics Market size was valued at USD 11.29 billion in 2023 and is poised to grow from USD 12.24 billion in 2024 to USD 23.33 billion by 2032, growing at a CAGR of 8.4% during the forecast period (2025-2032).

The global pneumonia therapeutics market is experiencing growth driven by the rising pneumonia prevalence, particularly among the elderly and immunocompromised. Community-acquired pneumonia remains a notable concern, with increasing awareness surrounding the significance of early diagnosis and treatment. This impetus has spurred advancements in diagnostic techniques and assessment tools, enhancing treatment guidelines for healthcare providers. The market offers a diverse range of antibiotics, antiviral medications, and supportive therapies, alongside a focus on personalized medicine to develop targeted treatments. However, challenges such as antibiotic resistance and healthcare access disparities persist. Overall, ongoing medical advancements and demographic shifts indicate a promising trajectory for the pneumonia therapeutics market in the coming years.

Top-down and bottom-up approaches were used to estimate and validate the size of the Pneumonia Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Pneumonia Therapeutics Market Segments Analysis

Global Pneumonia Therapeutics Market is segmented by Product, Drug Class, Route of Administration, Mode of Infection, Age Group, Distribution Channel and region. Based on Product, the market is segmented into Drugs, Vaccines and Oxygen Therapy. Based on Drug Class, the market is segmented into Antibacterial Drugs, Antiviral Drugs and Antifungal Drugs. Based on Route of Administration, the market is segmented into Oral, Parenteral and Inhalation. Based on Mode of Infection, the market is segmented into Hospital-acquired Pneumonia (HAP), Community-acquired Pneumonia (CAP) and Ventilator-associated Pneumonia (VAP). Based on Age Group, the market is segmented into Pediatric, Adult and Geriatric. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Pneumonia Therapeutics Market

The pneumonia therapeutics market is primarily fueled by the widespread prevalence of pneumonia, which poses a serious health threat, especially among at-risk groups including the elderly, infants, and those with weakened immune systems. As the incidence of pneumonia continues to increase globally, there is an urgent need for effective treatment options to combat this illness. This growing demand for innovative and efficient therapeutic solutions contributes significantly to the expansion of the pneumonia therapeutics market. Addressing the healthcare needs of vulnerable populations highlights the necessity for advancements in pneumonia treatment, ultimately driving market growth in this crucial sector.

Restraints in the Pneumonia Therapeutics Market

A significant limitation within the Pneumonia Therapeutics market is the issue of antibiotic resistance. The overuse and improper use of antibiotics have led to the development of drug-resistant bacterial strains, which pose a considerable challenge in effectively treating pneumonia. This growing resistance diminishes the effectiveness of existing treatment options and highlights an urgent need for innovative and alternative therapeutic approaches. As conventional antibiotics become less viable, healthcare providers and researchers are compelled to explore new strategies to combat pneumonia, underscoring the importance of addressing this restraint in the ongoing development of pneumonia treatments.

Market Trends of the Pneumonia Therapeutics Market

The pneumonia therapeutics market is witnessing a significant trend driven by an increased focus on drug development and research to address the challenges posed by drug-resistant bacterial strains. Pharmaceutical companies are channeling substantial investments into creating innovative antibiotics and alternative therapeutic strategies to enhance treatment efficacy. This momentum is underscored by the urgent need to combat the rising prevalence of antibiotic-resistant infections, which poses a serious public health threat. As a result, the landscape of pneumonia therapeutics is evolving, with stakeholders prioritizing advanced research initiatives that promise to redefine treatment paradigms and improve patient outcomes in the face of growing microbial resistance.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape
• Patent Analysis

Global Pneumonia Therapeutics Market Size by Product & CAGR (2025-2032)

• Market Overview
• Drugs
• Vaccines
• Oxygen Therapy

Global Pneumonia Therapeutics Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Antibacterial Drugs
• Antiviral Drugs
• Antifungal Drugs

Global Pneumonia Therapeutics Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Parenteral
• Inhalation

Global Pneumonia Therapeutics Market Size by Mode of Infection & CAGR (2025-2032)

• Market Overview
• Hospital-acquired Pneumonia (HAP)
• Community-acquired Pneumonia (CAP)
• Ventilator-associated Pneumonia (VAP)

Global Pneumonia Therapeutics Market Size by Age Group & CAGR (2025-2032)

• Market Overview
• Pediatric
• Adult
• Geriatric

Global Pneumonia Therapeutics Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Pneumonia Therapeutics Market Size & CAGR (2025-2032)

• North America (Product, Drug Class, Route of Administration, Mode of Infection, Age Group, Distribution Channel)
  • US
  • Canada
• Europe (Product, Drug Class, Route of Administration, Mode of Infection, Age Group, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Drug Class, Route of Administration, Mode of Infection, Age Group, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Drug Class, Route of Administration, Mode of Infection, Age Group, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Drug Class, Route of Administration, Mode of Infection, Age Group, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Inc. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Pharmaceuticals Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nabriva Therapeutics AG (Austria)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biotest AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SetLance SRL (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations